Notice of Intent to Publish a Funding Opportunity Announcement for Coordinating Center for Type 1 Diabetes TrialNet (U01 Clinical Trial Required)
Notice NOT-DK-24-004 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 18, 2023 Category: Research Source Type: funding
Notice of Intent to Publish a Funding Opportunity Announcement for Type 1 Diabetes TrialNet Clinical Network Hub (U01 Clinical Trial Not Allowed)
Notice NOT-DK-24-005 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 18, 2023 Category: Research Source Type: funding
Going For Gold and Beyond in the Rural Midwest: Grant for Health Care Organizations
Grants for rural healthcare organizations in the Midwest to lead evidence-based policy and practice changes in the areas of blood pressure, cholesterol, and type 2 diabetes. Geographic coverage: The Midwest region of the American Heart Association -- American Heart Association (Source: Funding opportunities via the Rural Health Information Hub)
Source: Funding opportunities via the Rural Health Information Hub - December 16, 2023 Category: American Health Source Type: funding
Cardiovascular Repository Type 1 Diabetes (CARE-T1D) Consortium (U01 Clinical Trial Not Allowed).
Funding Opportunity RFA-DK-23-021 from the NIH Guide for Grants and Contracts. Cardiovascular complications are the leading cause of death for individuals with type 1 diabetes (T1D) and significantly shorten their lives. Cardiovascular disease (CVD) progression in people with T1D differs from that observed in people with type 2 diabetes (T2D) and residual increased risk of CVD remains after treatment of standard risk factors, such as hyperglycemia, hypertension, and hyperlipidemia. The NIH Cardiovascular Repository for T1D (CaRe-T1D) was initiated with the goal of establishing a biorepository of human CV tissue and a sc...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 30, 2023 Category: Research Source Type: funding
Notice of Change to Letter of Intent Due Date for RFA-DK-23-004: Human Islet Research Network - Consortium on Modeling Autoimmune Diabetes (HIRN-CMAD) (UG3/UH3 Clinical Trial Not Allowed)
Notice NOT-DK-24-002 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 9, 2023 Category: Research Source Type: funding
Notice of Special Interest: Administrative Supplements to Support Emerging Physician-Scientists to Develop Research Expertise in Diabetes, Endocrinology and Metabolic Diseases
Notice NOT-DK-23-021 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 30, 2023 Category: Research Source Type: funding
Single Source for continuation of the Human Pancreas Analysis Program for Type-2 Diabetes (HPAP-T2D) (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-DK-25-002 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites cooperative agreement applications to expand the operational scope of the existing Human Pancreas Analysis Program (HPAP) to the study of pancreata recovered from tissue donors with Type 2 Diabetes (T2D) and related metabolic disorders. This NOFO will support one team of investigators with combined expertise in human pancreas physiology and pathophysiology; collection, processing and multimodal analysis of human pancreatic tissues; and biological database building, curation and management, tha...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 24, 2023 Category: Research Source Type: funding
Notice of Intent to Publish a Funding Opportunity Announcement for Cardiovascular Repository Type 1 Diabetes (CARE-T1D) Consortium (U01 Clinical Trial Not Allowed).
Notice NOT-DK-24-001 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 20, 2023 Category: Research Source Type: funding
Human Islet Research Network - Consortium on Modeling Autoimmune Diabetes (HIRN-CMAD) (UG3/UH3 Clinical Trial Not Allowed)
Funding Opportunity RFA-DK-23-004 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) welcomes applications for the Consortium on Modeling Autoimmune Diabetes (CMAD) that supports the development of in vitro and in vivo models of type 1 diabetes (T1D) to enable studies of human T1D pathophysiology and to serve as platforms for preclinical assessments of new T1D interventions. CMAD is part of the Human Islet Research Network (HIRN). (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 11, 2023 Category: Research Source Type: funding
Single Source for the Continuation of the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) Data Coordinating Center (U24 Clinical Trial Required)
Funding Opportunity RFA-DK-23-516 from the NIH Guide for Grants and Contracts. This is a non-competitive notice of funding opportunity (NOFO) intended to fund a single award. The National Institute of Diabetes and Digestive and Kidney Disorders (NIDDK) is announcing its intent to issue a single source cooperative agreement to Johns Hopkins University to continue the support of the Data Coordinating Center of the NASH Clinical Research Network (NASH CRN) as they complete and report their active clinical treatment trial, and close out, analyze, and report the networks prospective database (DB3).The NASH CRN has been spons...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 7, 2023 Category: Research Source Type: funding
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
Funding Opportunity PAR-23-280 from the NIH Guide for Grants and Contracts. The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increa...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 24, 2023 Category: Research Source Type: funding
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
Funding Opportunity PAR-23-279 from the NIH Guide for Grants and Contracts. The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increa...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 23, 2023 Category: Research Source Type: funding
The Role of Sleep Deficiency in Persons with Type 1 Diabetes: Sleep, Glycemic Control, and Cardiovascular Risk (R34 Clinical Trial Optional)
Funding Opportunity RFA-HL-24-009 from the NIH Guide for Grants and Contracts. This NOFO will support preliminary studies aimed to obtain information necessary to guide the design of a full randomized control trial to test whether sleep and circadian targeted interventions improve the clinical course and treatment outcomes in individuals with Type 1 Diabetes (T1D). Applications should focus on pilot studies to inform practical and potentially sustainable strategies to improve processes of care and cardiometabolic health outcomes in individuals with T1D. The scope of research for this NOFO includes a range of feasibility...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 20, 2023 Category: Research Source Type: funding
The Role of Sleep Deficiency in Persons with Type 1 Diabetes: Sleep, Glycemic Control, and Cardiovascular Risk (R01 Clinical Trial Optional)
Funding Opportunity RFA-HL-24-008 from the NIH Guide for Grants and Contracts. The purpose of this NOFO is to elucidate the contribution of sleep deficiency and circadian disruption to metabolic and cardiovascular pathobiology, disease trajectory, and treatment response in individuals living with Type 1 Diabetes (T1D). The RFA will support clinically relevant, mechanism focused research on the interface between sleep, circadian rhythms biology, T1D and cardiovascular disease. Multi-disciplinary teams bridging sleep/circadian, diabetes, and cardiovascular research are encouraged. Proposed research should be relevant to t...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 20, 2023 Category: Research Source Type: funding
Notice of Pre-Application Webinar for Evaluating Neurocognitive Complications of Pediatric Type 1 Diabetes (T1D) and Potential Risk and Protective Factors (RFA-DK-23-009/RFA-DK-23-010)
Notice NOT-DK-23-028 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 30, 2023 Category: Research Source Type: funding
